Sex-specific and immune-cell-specific contributions of CD18 in myocardial ischemia-reperfusion injury

Zhichao Fan,Wei Liu,Chunxia G. Cronin,Lai Wen,Klaus Ley,Bruce T. Liang
DOI: https://doi.org/10.4049/jimmunol.210.Supp.70.07
2023-01-01
Abstract:Abstract Leukocyte recruitment and their mediated inflammatory responses are critical for cardiovascular diseases, including myocardial ischemia-reperfusion (I/R) injury. Blocking leukocyte recruitment in mouse knockouts (KO) of beta2 integrin (CD18) or blocking CD18 with antibodies in multiple animals significantly reduced infarct size after myocardial I/R injury. However, the cell-specific contribution of leukocyte CD18 to I/R injury is unknown. In this study, we used the newly established CD18 flox/flox(hITGB2 KI) mice to address this knowledge gap. We crossed them to CSF1R-cre (CD115) and MRP8-cre (S100A8) and tested the KO of CD18 in different leukocytes. Interestingly, CSF1R-cre CD18 flox/floxunexpectedly deleted CD18 in all peripheral blood leukocytes, including neutrophils, monocytes, CD4 T cells, CD8 T cells, B cells, and NK cells. It also elevated the cell number of these leukocytes in peripheral blood. In MRP8-cre CD18 flox/floxmice, CD18 was only knocked out in neutrophils but not other peripheral blood leukocytes. And only neutrophil number was elevated in peripheral blood. After 35 minutes of myocardial ischemia and 24 hours of reperfusion, we found both CSF1R-cre CD18 flox/floxand MRP8-cre CD18 flox/floxmice have significantly reduced infarct size compared to cre-controls. However, if we distinguish the sex in analysis, we only found a significant alleviation in female but not male CSF1R-cre CD18 flox/floxmice. In contrast, we observed a significant alleviation only in male but not female MRP8-cre CD18 flox/floxmice. These results suggested sex-specific and immune-cell-specific contributions of CD18 in myocardial ischemia-reperfusion injury and provided new insights into CD18 targeting therapies. This research was supported by grants from the National Institutes of Health, National Heart, Lung, and Blood Institute, USA (R01HL145454, R41HL156322, and R44HL152710) and a startup fund from UConn Health.
What problem does this paper attempt to address?